Is suppression of inflammation in ulcerative colitis by interferon-β-1a accompanied by inhibition of IL-13 production?
Interferon-β-1a induces clinical response and remission in a large subset of patients with ulcerative colitis that is associated with significant inhibition of IL-13 production. In addition, increased IL-17 and IL-6 production is associated with no response to interferon-β. These data provide a proof-of-concept that IL-13 is an effector cytokine in ulcerative colitis and should be a target for novel therapies.
Maternal and pediatric perceptions of readiness for postpartum discharge of mothers and infants show substantial variation on the day of discharge and over time.